Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Annexon, Inc.

NASDAQ: ANNX · Life Sciences · 2 alerts · CIK 1528115

Share price
$3.57Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Annexon, Inc. filings on SEC EDGAR ↗

4:09 PM ET 10-Q
Financial Results

Annexon Q3 2026 Results: Net Loss of $51.2M, Loss Narrows

Annexon, Inc. reported a net loss of $150.7 million for the nine months ended September 30, 2026, compared to $158.4 million in the prior year period. The company strengthened its balance sheet through a $49.3 million term loan and common stock issuances, ending the period with $213.4 million in cash, cash equivalents, and short-term investments.

Key figure
Net loss $51.2M
4:06 PM ET 8-K
Financial Results

Annexon Financial Results

Annexon reported Q3 2026 financial results, highlighting a cash position of $213 million providing a runway into 2028. The company is preparing for a U.S. BLA submission for tanruprubart in GBS in Q4 2026 and expects a primary endpoint readout for its Phase 3 ARCHER II trial in geographic atrophy in Q4 2026.

Term
Q3 2026

“Annexon is well-positioned for a transformative next 12 months, with multiple value-creating milestones expected across our differentiated upstream C1q platform. By targeting C1q tanruprubart and vonaprument have each demonstrated first-in-kind benefits in clinical trials to date, with tanruprubart accelerating functional recovery in Guillain-Barré syndrome (GBS) and vonaprument protecting vision in geographic atrophy (GA).”

Douglas Love, President and Chief Executive Officer of Annexon

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.